| Customization: | Available |
|---|---|
| Dosage Form: | Powder Injection |
| Dossier: | Ready |
|
Still deciding? Get samples of US$ 0.1/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Generic Name | Piperacillin Sodium and Tazobactam Sodium for Injection 4.5g |
| Strength | 4.5g |
| Packing | 10 vials/box |
| Origin | China |
Piperacillin/trizobactam is indicated for the treatment of the following systemic and/or local bacterial infections caused by detected or suspected sensitive bacteria.
1. Lower respiratory tract infection.
2. Urinary tract infection (mixed infection or single bacterial infection)
3. Intraperitoneal infection.
4. Skin and soft tissue infection.
5. Bacterial sepsis.
6. Gynecological infection.
7. In combination with aminoglycosides for bacterial infections in patients with neutropenia.
8. Bone and joint infections.
9. Multiple bacterial infections; Piperacillin/trizobactam is indicated for the treatment of a wide range of bacterial co-infections, including those in which aerobic and anaerobic bacteria are suspected to be present at the site of infection (intraperitoneal, skin and soft tissue, upper and lower respiratory tract, gynecology).
Although piperacillin/trizobactam is only applicable in the above cases, piperacillin/trizobactam is tested for the treatment of infections caused by piperacillin-sensitive bacteria due to its component in piperacillin. Therefore, the treatment of mixed infections caused by piperacillin sensitive bacteria and piperacillin/trizobactam sensitive β-lactamase producing bacteria is not necessary to add another antibiotic.
Appropriate bacterial cultures and susceptibility tests should be performed prior to treatment to identify the organism causing the infection and to determine the susceptibility of the pathogen to piperacillin/trizobactam. Because piperacillin/trizobactam has a broad spectrum of antibacterial activity against gram-positive and gram-negative, aerobic and anaerobic bacteria as listed above, it is highly effective for the treatment of mixed infections and for empirical treatment when susceptibility test results are not yet available. However, although piperacillin/trizobactam may be used until susceptibility test results are reported, treatment regimens need to be modified once susceptibility results are obtained or there is no clinical response to treatment.
In the case of severe infection, piperacillin/trizobactam may be initiated as an empiric treatment before the results of the susceptibility test are reported.
The combination of piperacillin/trizobactam and aminoglycoside antibiotics has a synergistic effect in the treatment of certain strains of P. aeruginosa infection. Especially in cases where the patient's host defense system is compromised, the combination of drugs is successful. The full therapeutic dose should be used for both drugs. Antibiotic therapy should be adjusted once bacterial culture and susceptibility test results are reported.
Patients with neutropenia should be treated with a full dose of piperacillin/trizobactam and an aminoglycoside antibiotic, and patients with low potassium reserves should be alert to the possibility of hypokalemia, and electrolyte levels should be measured regularly in such patients.
Step 1 Dose
This product must be administered by slow intravenous drip (more than 20-30 minutes of administration) or slow intravenous drip (at least 3-5 minutes).
Adults and youth 12 years and older
The usual dose for adults and adolescents with normal kidney function is 4.5g piperacillin/trizobactam given every 8 hours.
The total daily dose increases or decreases depending on the severity and site of infection and can range from 2.25g piperacillin/trizobactam once every 6, 8, or 12 hours to 4.5g piperacillin/trizobactam.
When piperacillin/trizobactam is combined with another antibiotic (e.g., an aminoglycoside drug), it must be administered separately. Piperacillin/trizobactam can cause substantial inactivation of aminoglycosides in vitro. When the two drugs are used in combination, they should be prepared, diluted and administered separately. (See Drug Interactions)
2. Renal insufficiency
For patients with renal insufficiency (creatinine clearance ≤40 mL/ min) or hemodialysis patients, the dosage and interval of intravenous administration of this product (piperacillin for injection/trizobactam) should be adjusted according to the actual degree of renal impairment. Patients with hospital-acquired pneumonia who are co-treated with aminoglycosides should adjust the aminoglycoside dose as recommended by the manufacturer. The recommended daily dose for patients with renal insufficiency is as follows:
Intravenous dosimeter for impaired renal function in adults
Endogenous creatinine clearance (ml/min) The recommended dose of piperacillin/trizobactam
> 40 No adjustment required
20-40 13.5g/ day, 4.5g/ time, q.8.H
< 20 9g/ day dose, 4.5g/ time, q.12.H
In patients on hemodialysis, the maximum dose for all indications except hospital-acquired pneumonia is 2.25g q12h. The maximum dose for hospital-acquired pneumonia was 2.25g q8h. Because hemodialysis can remove 30% to 40% of the administered dose, an additional 0.75g of this product is required on the day of hemodialysis after each dialysis operation. Continuous ambulatory peritoneal dialysis (CAPD) patients do not need additional use of this product.
A. Special warning
Prior to starting piperacillin/trizobactam treatment, a history of previous allergic reactions to penicillin, cephalosporins, and other allergens should be carefully asked. Severe and occasionally fatal allergic (anaphylactic/anaphylactoid [including shock]) reactions have been reported in people treated with penicillins (including piperacillin/trizobactam). These reactions are more likely to occur in patients with previous allergies to multiple allergens. Severe allergic reactions require discontinuation of antibiotic treatment and may require the administration of epinephrine and other emergency measures such as oxygen, intravenous corticosteroids, airway management (including tracheal intubation).
Pseudomembranous colitis has been reported with almost all antimicrobials, including piperacillin/trizobactam. Any antibiotic-induced pseudomembranous enteritis may present as severe, persistent diarrhea ranging from mild to life-threatening. Symptoms of pseudomembranous enteritis may appear during or after antimicrobial therapy. Therefore, patients who develop diarrhea after using antibiotics should take this diagnosis into account.
Antimicrobial treatment alters the normal flora of the colon, possibly allowing clostridium to overgrow. Research has shown that a toxin produced by Clostridium difficile is one of the main causes of "antibiotic-associated colitis."
Once pseudomembranous colitis is diagnosed, treatment should be initiated. Mild patients only need to stop antibiotics, and moderate to severe patients need to consider maintaining fluid and electrolyte balance, protein supplementation, and antibiotics that are clinically effective against Clostridium difficile colitis.
){kind=link}